Statins inhibit Rho kinase activity in patients with atherosclerosis

Anju Nohria, Adnan Prsic, Ping-Yen Liu, Ryuji Okamoto, Mark A. Creager, Andrew Selwyn, James K. Liao, Peter Ganz

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background: In addition to inhibiting cholesterol synthesis, statins (HMG-CoA reductase inhibitors) decrease the formation of isoprenoid intermediates required for the activation of key signaling pathways, including Rho/Rho kinase (ROCK). In experimental settings, statins inhibit ROCK and reverse vascular dysfunctions in atherosclerosis, independent of cholesterol reduction. It is not known whether statins inhibit ROCK activity in humans with atherosclerosis. Methods: We investigated 35 patients with stable atherosclerosis in a randomized, double-blind study comparing treatment with high-dose (80 mg/d) or low-dose (10 mg/d) atorvastatin to placebo for 28 days. Blood samples for leukocyte ROCK activity, fasting lipids, and high-sensitivity C-reactive protein (hs-CRP) were obtained on days 0, 7, 14, and 28 after randomization and change over time with the two statin treatments relative to placebo was examined. Results: Atorvastatin 80 mg/d reduced ROCK activity (p = 0.002 vs. placebo). This decline was rapid and significant within 2 weeks of treatment. The inhibition of ROCK by atorvastatin (80 mg/d) remained significant even after controlling for changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (p = 0.01). Furthermore, there was no correlation between changes in ROCK activity and changes in LDL-C (r = 0.2, p = 0.25) or triglycerides (r = 0.1, p = 0.55). There was a modest correlation between ROCK inhibition and change in hs-CRP among patients randomized to atorvastatin 80 mg/d (r = 0.6, p = 0.07). Conclusions: These first-in-man findings demonstrate that high-dose atorvastatin rapidly inhibits the pro-atherogenic Rho/ROCK pathway, independent of cholesterol reduction. This inhibition may contribute to the clinical benefits of statins. Rho/ROCK may provide a useful therapeutic target in patients with atherosclerosis.

Original languageEnglish
Pages (from-to)517-521
Number of pages5
JournalAtherosclerosis
Volume205
Issue number2
DOIs
Publication statusPublished - 2009 Aug 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
rho-Associated Kinases
Atherosclerosis
Cholesterol
Placebos
C-Reactive Protein
LDL Cholesterol
Terpenes
Therapeutics
Random Allocation
Double-Blind Method
Human Activities
Blood Vessels
Fasting
Triglycerides
Leukocytes
Atorvastatin Calcium
Lipids
Inhibition (Psychology)

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Nohria, A., Prsic, A., Liu, P-Y., Okamoto, R., Creager, M. A., Selwyn, A., ... Ganz, P. (2009). Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 205(2), 517-521. https://doi.org/10.1016/j.atherosclerosis.2008.12.023
Nohria, Anju ; Prsic, Adnan ; Liu, Ping-Yen ; Okamoto, Ryuji ; Creager, Mark A. ; Selwyn, Andrew ; Liao, James K. ; Ganz, Peter. / Statins inhibit Rho kinase activity in patients with atherosclerosis. In: Atherosclerosis. 2009 ; Vol. 205, No. 2. pp. 517-521.
@article{0f32074369054f9188d75fb848a43a15,
title = "Statins inhibit Rho kinase activity in patients with atherosclerosis",
abstract = "Background: In addition to inhibiting cholesterol synthesis, statins (HMG-CoA reductase inhibitors) decrease the formation of isoprenoid intermediates required for the activation of key signaling pathways, including Rho/Rho kinase (ROCK). In experimental settings, statins inhibit ROCK and reverse vascular dysfunctions in atherosclerosis, independent of cholesterol reduction. It is not known whether statins inhibit ROCK activity in humans with atherosclerosis. Methods: We investigated 35 patients with stable atherosclerosis in a randomized, double-blind study comparing treatment with high-dose (80 mg/d) or low-dose (10 mg/d) atorvastatin to placebo for 28 days. Blood samples for leukocyte ROCK activity, fasting lipids, and high-sensitivity C-reactive protein (hs-CRP) were obtained on days 0, 7, 14, and 28 after randomization and change over time with the two statin treatments relative to placebo was examined. Results: Atorvastatin 80 mg/d reduced ROCK activity (p = 0.002 vs. placebo). This decline was rapid and significant within 2 weeks of treatment. The inhibition of ROCK by atorvastatin (80 mg/d) remained significant even after controlling for changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (p = 0.01). Furthermore, there was no correlation between changes in ROCK activity and changes in LDL-C (r = 0.2, p = 0.25) or triglycerides (r = 0.1, p = 0.55). There was a modest correlation between ROCK inhibition and change in hs-CRP among patients randomized to atorvastatin 80 mg/d (r = 0.6, p = 0.07). Conclusions: These first-in-man findings demonstrate that high-dose atorvastatin rapidly inhibits the pro-atherogenic Rho/ROCK pathway, independent of cholesterol reduction. This inhibition may contribute to the clinical benefits of statins. Rho/ROCK may provide a useful therapeutic target in patients with atherosclerosis.",
author = "Anju Nohria and Adnan Prsic and Ping-Yen Liu and Ryuji Okamoto and Creager, {Mark A.} and Andrew Selwyn and Liao, {James K.} and Peter Ganz",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.atherosclerosis.2008.12.023",
language = "English",
volume = "205",
pages = "517--521",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Nohria, A, Prsic, A, Liu, P-Y, Okamoto, R, Creager, MA, Selwyn, A, Liao, JK & Ganz, P 2009, 'Statins inhibit Rho kinase activity in patients with atherosclerosis', Atherosclerosis, vol. 205, no. 2, pp. 517-521. https://doi.org/10.1016/j.atherosclerosis.2008.12.023

Statins inhibit Rho kinase activity in patients with atherosclerosis. / Nohria, Anju; Prsic, Adnan; Liu, Ping-Yen; Okamoto, Ryuji; Creager, Mark A.; Selwyn, Andrew; Liao, James K.; Ganz, Peter.

In: Atherosclerosis, Vol. 205, No. 2, 01.08.2009, p. 517-521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statins inhibit Rho kinase activity in patients with atherosclerosis

AU - Nohria, Anju

AU - Prsic, Adnan

AU - Liu, Ping-Yen

AU - Okamoto, Ryuji

AU - Creager, Mark A.

AU - Selwyn, Andrew

AU - Liao, James K.

AU - Ganz, Peter

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: In addition to inhibiting cholesterol synthesis, statins (HMG-CoA reductase inhibitors) decrease the formation of isoprenoid intermediates required for the activation of key signaling pathways, including Rho/Rho kinase (ROCK). In experimental settings, statins inhibit ROCK and reverse vascular dysfunctions in atherosclerosis, independent of cholesterol reduction. It is not known whether statins inhibit ROCK activity in humans with atherosclerosis. Methods: We investigated 35 patients with stable atherosclerosis in a randomized, double-blind study comparing treatment with high-dose (80 mg/d) or low-dose (10 mg/d) atorvastatin to placebo for 28 days. Blood samples for leukocyte ROCK activity, fasting lipids, and high-sensitivity C-reactive protein (hs-CRP) were obtained on days 0, 7, 14, and 28 after randomization and change over time with the two statin treatments relative to placebo was examined. Results: Atorvastatin 80 mg/d reduced ROCK activity (p = 0.002 vs. placebo). This decline was rapid and significant within 2 weeks of treatment. The inhibition of ROCK by atorvastatin (80 mg/d) remained significant even after controlling for changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (p = 0.01). Furthermore, there was no correlation between changes in ROCK activity and changes in LDL-C (r = 0.2, p = 0.25) or triglycerides (r = 0.1, p = 0.55). There was a modest correlation between ROCK inhibition and change in hs-CRP among patients randomized to atorvastatin 80 mg/d (r = 0.6, p = 0.07). Conclusions: These first-in-man findings demonstrate that high-dose atorvastatin rapidly inhibits the pro-atherogenic Rho/ROCK pathway, independent of cholesterol reduction. This inhibition may contribute to the clinical benefits of statins. Rho/ROCK may provide a useful therapeutic target in patients with atherosclerosis.

AB - Background: In addition to inhibiting cholesterol synthesis, statins (HMG-CoA reductase inhibitors) decrease the formation of isoprenoid intermediates required for the activation of key signaling pathways, including Rho/Rho kinase (ROCK). In experimental settings, statins inhibit ROCK and reverse vascular dysfunctions in atherosclerosis, independent of cholesterol reduction. It is not known whether statins inhibit ROCK activity in humans with atherosclerosis. Methods: We investigated 35 patients with stable atherosclerosis in a randomized, double-blind study comparing treatment with high-dose (80 mg/d) or low-dose (10 mg/d) atorvastatin to placebo for 28 days. Blood samples for leukocyte ROCK activity, fasting lipids, and high-sensitivity C-reactive protein (hs-CRP) were obtained on days 0, 7, 14, and 28 after randomization and change over time with the two statin treatments relative to placebo was examined. Results: Atorvastatin 80 mg/d reduced ROCK activity (p = 0.002 vs. placebo). This decline was rapid and significant within 2 weeks of treatment. The inhibition of ROCK by atorvastatin (80 mg/d) remained significant even after controlling for changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (p = 0.01). Furthermore, there was no correlation between changes in ROCK activity and changes in LDL-C (r = 0.2, p = 0.25) or triglycerides (r = 0.1, p = 0.55). There was a modest correlation between ROCK inhibition and change in hs-CRP among patients randomized to atorvastatin 80 mg/d (r = 0.6, p = 0.07). Conclusions: These first-in-man findings demonstrate that high-dose atorvastatin rapidly inhibits the pro-atherogenic Rho/ROCK pathway, independent of cholesterol reduction. This inhibition may contribute to the clinical benefits of statins. Rho/ROCK may provide a useful therapeutic target in patients with atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=67650902217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650902217&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.12.023

DO - 10.1016/j.atherosclerosis.2008.12.023

M3 - Article

C2 - 19167712

AN - SCOPUS:67650902217

VL - 205

SP - 517

EP - 521

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -